Hepatocyte damage

Hepatocyte damage refers to the structural and functional impairment of hepatocytes, the primary parenchymal cells of the liver, which can lead to cell death through subroutines like apoptosis, necrosis, and ferroptosis. This process is triggered by a variety of insults, including viral infections (e.g., hepatitis B/C), metabolic disorders (e.g., NASH), and exposure to hepatotoxins or drugs. While not a singular molecular target, hepatocyte damage is a critical endpoint in clinical pharmacology and toxicology, serving as the primary indicator for drug-induced liver injury (DILI) and liver disease progression. Clinically, this damage is detected through the leakage of intracellular enzymes like alanine aminotransferase (ALT) and aspartate aminotransferase (AST) into the bloodstream. Therapeutic interventions typically focus on preventing or reversing this damage by targeting underlying triggers such as oxidative stress, mitochondrial dysfunction, or pro-inflammatory signaling pathways like TNF-alpha and NLRP3 inflammasome activation.

Other names

Hepatocyte injuryHepatocellular injuryLiver cell damageHepatocyte deathHepatocellular damage

Hepatocyte damage is a pathological state rather than a target; however, hepatoprotective drugs like N-acetylcysteine act by restoring glutathione levels to neutralize reactive metabolites, while hepatotoxic drugs induce damage via cytochrome P450-mediated reactive metabolite formation, mitochondrial dysfunction, and immune-mediated inflammatory responses.